UBS analyst Ashwani Verma lowered the firm’s price target on United Therapeutics to $310 from $330 and keeps a Buy rating on the shares ahead of the Q1 results. The firm is modeling unchanged Q1 total sales and EPS of $508M and $4.37, respectively, which is slightly below consensus, and notes that Q1 can be seasonally soft for Tyvaso/Remodulin, the analyst tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on UTHR:
